Determining the Contribution of Hyperlipidemia to Mortality Post anesthesia in Patients who are Candidates for Coronary Artery Graft Surgery

Introduction: Statins are powerful lipid-lowering drugs that have been shown to be effective in preventing heart disease and reducing the risk of death and heart attack. It is unclear whether hyperlipidemic patients undergoing coronary artery bypass grafting benefit from the lipid-lowering effects of statins. We sought to determine whether prior statin therapy could affect the outcome of hyperlipidemic patients undergoing coronary artery bypass grafting. Material and Methods: In this cross-sectional descriptive study conducted between 2012 and 2015, hyperlipidemia to mortality post anesthesia in patients who are candidates for coronary artery graft surgery was investigated. Results: Risk-adjusted multivariate logistic regression analysis showed that statin-treated hyperlipidemic (odds ratio, 0.42; 95% confidence interval, 0.26-0.69; P = .0007) ratio was 0.42; confidence interval, 0.26-0.69; P = .0007) was independently associated with a reduction in major in-hospital cardiac events, but not in-hospital mortality. A similarity score based on the previous 14 risk factors was performed to further control for bias. After similar correlations, randomized controlled trials confirmed that statin-treated hyperlipidemia and non-statin-treated eulipidemia were associated with reductions in major cardiovascular hospitalizations (difference odds ratio, 0.41; 95% confidence, 0.24-=0.71 [P. .0013] and odds) rate is 0. Conclusion: Although there was no increase in MACE in these normolipidemic patients who did not receive prior statin therapy, results from other CABG studies 6,7,8,9,16 and 25 in patients with heart disease were background in all patients who received CABG. LDL-C levels may benefit from long-term statin therapy. Although some of these patients did not see immediate short-term benefit, this study did not examine the long-term outcomes and future cardiovascular events of MACE. This group of patients may also benefit from a reduction in long-term MACE with statin therapy despite low preoperative LDL-C levels